Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TLX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| 177Lu-TLX591 | Metastatic Castration-resistant Prostate Cancer | Phase 3 · NCT06520345 | Recruiting |
| Gallium Ga 68 Gozetotide | Prostate Cancer | Phase 3 · NCT05744115 | Terminated |
| F-18 Fluoroethyltyrosine | Brain Metastasis | Phase 3 · NCT07931261 | Not yet recruiting |
| Zirconium Zr 89 Girentuximab | Clear Cell Renal Cell Carcinoma | Phase 3 · NCT06750419 | Recruiting |
| ArabinoFuranosylGuanine [18F]F-AraG | Advanced Cancer | Phase 1/2 · NCT05663710 | Recruiting |
| PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC | Prostate Cancer | Phase 2 · NCT04402151 | Recruiting |
| Fluciclovine F18 | Prostate Adenocarcinoma | Phase 2 · NCT03762759 | Active not recruiting |
| 177Lu-TLX250 | ccRCC | Phase 2 · NCT07870746 | Not yet recruiting |
| Lutetium Lu 177 Rosopatamab Tetraxetan | Prostate Cancer | Phase 2 · NCT05146973 | Completed |
| 177Lu girentuximab | Advanced Cancer | Phase 1/2 · NCT05663710 | Recruiting |
| Iodine I 131 IPA | Neoplastic Disease | Phase 1 · NCT05450744 | Active not recruiting |
| 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) | Soft Tissue Sarcoma | Phase 1 · NCT06537596 | Recruiting |
| 68-Ga PSMA11 | Prostate Adenocarcinoma | Phase 1 · NCT06044857 | Recruiting |
| Samarium Sm 153-DOTMP | Bone Pain | Phase 1 · NCT07197645 | Recruiting |
| Drug: 68-Ga PSMA11 | Prostate Cancer | Early Phase 1 · NCT07674771 | Not yet recruiting |
| Copper Cu 64-DOTA-TLX592 | Metastatic Prostate Cancer | Early Phase 1 · NCT04726033 | Completed |
Also used in these trials (approved or third-party drugs, not TLX's own candidates): Enzalutamide, Abiraterone Acetate, Docetaxel Anhydrous, Nivolumab, Cabozantinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TLX holds $251.9M in cash and short-term investments and burns about $3M/quarter from operations, an estimated runway of 251.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TLX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Christian Behrenbruch MD & Group CEO, Director |
Insider | 20,742,935 | 6.12% | 2026-04-28 |
| Mark Alexander Nelson Director |
Insider | 3,628,750 | 1.07% | 2026-03-18 |
| Jann Elizabeth Skinner Director |
Insider | 595,000 | 0.18% | 2026-03-18 |
| David Norman Cade Group Chief Medical Officer |
Insider | 373,133 | 0.11% | 2026-03-18 |
| Darren Charlton Smith Group Chief Financial Officer |
Insider | 13,992 | 0.00% | 2026-09-07 |
| Marie Elizabeth McDonald Director |
Insider | 3,719 | 0.00% | 2026-03-18 |
| Darren Joel Patti Group Chief Operating Officer |
Insider | 804 | 0.00% | 2026-03-18 |
Share count 338,777,049 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TLX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →